ME01031B - Djeljivi galenski oblik koji omogućava modifikovano oslobađanje aktivnog sastojka - Google Patents

Djeljivi galenski oblik koji omogućava modifikovano oslobađanje aktivnog sastojka

Info

Publication number
ME01031B
ME01031B MEP-2010-154A MEP15410A ME01031B ME 01031 B ME01031 B ME 01031B ME P15410 A MEP15410 A ME P15410A ME 01031 B ME01031 B ME 01031B
Authority
ME
Montenegro
Prior art keywords
divisible
active ingredient
modified release
galenic form
form allowing
Prior art date
Application number
MEP-2010-154A
Other languages
English (en)
French (fr)
Inventor
Gilles Fonknechten
Patrick Genty
Jean-Manuel Pean
Patrick Wuthrich
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39796790&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME01031(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of ME01031B publication Critical patent/ME01031B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Inorganic Chemistry (AREA)

Abstract

Deljivl galenski oblik sa modifikovanim oslobadanjem aktivnog sastojka, pri cemu ne-podeljeni galenski oblik i deo navedenog oblika dobijen deljenjem na manje delove imaju iste profile rastvaranja.
MEP-2010-154A 2008-03-21 2009-03-20 Djeljivi galenski oblik koji omogućava modifikovano oslobađanje aktivnog sastojka ME01031B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0801561A FR2928836B1 (fr) 2008-03-21 2008-03-21 Forme galenique secable permettant une liberation modifiee du principe actif
PCT/FR2009/000295 WO2009125087A1 (fr) 2008-03-21 2009-03-20 Forme galenique secable permettant une liberation modifiee du principe actif

Publications (1)

Publication Number Publication Date
ME01031B true ME01031B (me) 2012-10-20

Family

ID=39796790

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2010-154A ME01031B (me) 2008-03-21 2009-03-20 Djeljivi galenski oblik koji omogućava modifikovano oslobađanje aktivnog sastojka

Country Status (37)

Country Link
US (3) US20090238870A1 (me)
EP (2) EP2103302A1 (me)
JP (2) JP5231906B2 (me)
KR (3) KR20090101048A (me)
CN (1) CN101347414B (me)
AP (1) AP2729A (me)
AR (1) AR067993A1 (me)
AU (1) AU2008207680B8 (me)
BR (1) BRPI0803631A2 (me)
CA (1) CA2629670C (me)
CL (1) CL2008002486A1 (me)
CO (1) CO6020017A1 (me)
CR (2) CR10317A (me)
CU (1) CU23970B1 (me)
EA (1) EA200801862A1 (me)
EC (1) ECSP088727A (me)
FR (1) FR2928836B1 (me)
GT (1) GT200800163A (me)
HK (1) HK1127280A1 (me)
HN (1) HN2008001466A (me)
IL (1) IL193611A0 (me)
JO (1) JO3052B1 (me)
MA (1) MA31218B1 (me)
ME (1) ME01031B (me)
MX (1) MX2008011579A (me)
MY (1) MY150660A (me)
NI (1) NI200800256A (me)
NZ (1) NZ570715A (me)
PE (1) PE20090991A1 (me)
SA (1) SA08290555B1 (me)
SG (1) SG155819A1 (me)
SV (1) SV2008003023A (me)
TW (1) TWI396561B (me)
UA (1) UA86731C2 (me)
UY (1) UY31307A1 (me)
WO (1) WO2009125087A1 (me)
ZA (1) ZA200807354B (me)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0615860B8 (pt) 2005-09-09 2021-05-25 Labopharm Barbados Ltd composição farmacêutica de liberação prolongada monolítica sólida
US20070160960A1 (en) * 2005-10-21 2007-07-12 Laser Shot, Inc. System and method for calculating a projectile impact coordinates
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TR201103946A1 (tr) 2011-04-22 2012-11-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım sağlayan gliklazid formülasyonları.
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ITFI20130184A1 (it) * 2013-08-01 2015-02-02 Valpharma Internat S P A Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
CN106892856A (zh) * 2017-02-06 2017-06-27 山东科源制药股份有限公司 一种格列齐特粗品重结晶的制备方法
MX2022011505A (es) 2020-03-16 2022-10-07 Gruenenthal Gmbh Comprimido ranurado.

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353887A (en) * 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
CH648754A5 (en) * 1979-08-16 1985-04-15 Ciba Geigy Ag Pharmaceutical slow release tablet
US4851230A (en) * 1983-04-07 1989-07-25 Bristol-Myers Company Capsule shaped tablets
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
JPH069375A (ja) * 1992-04-10 1994-01-18 Takeda Chem Ind Ltd 分割可能な連結錠剤
DE4229085C2 (de) * 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Längliche, teilbare Tablette
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
WO1999029314A1 (en) * 1997-12-08 1999-06-17 Bristol-Myers Squibb Company Novel salts of metformin and method
CA2320900C (en) * 1998-03-19 2009-10-27 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
ES2302364T3 (es) * 1998-04-03 2008-07-01 Kyowa Hakko Kogyo Co., Ltd. Tableta divisible y paquete perforado por presion.
JP2006052230A (ja) * 1998-04-03 2006-02-23 Kyowa Hakko Kogyo Co Ltd 分割錠剤及びプレススルーパック
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
US6667060B1 (en) * 1999-03-31 2003-12-23 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
US6878749B2 (en) * 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
DE10117208A1 (de) * 2001-04-06 2002-10-10 Wolff Walsrode Ag Verfahren zur Herstellung von niederviskosen, wässrigen Celluloseetherlösungen
CN1294908C (zh) * 2003-06-08 2007-01-17 安徽省医药科技实业公司 口服格列齐特缓释制剂
EP1741435A4 (en) * 2004-04-29 2009-11-11 Lotus Pharmaceutical Co Ltd ORAL VAPORS WITH MODIFIED RELEASE AND METHOD OF MANUFACTURING THEM
US7622137B2 (en) * 2004-05-21 2009-11-24 Accu-Break Technologies, Inc. Dosage forms contained within a capsule or sachet
EP1827453A1 (en) * 2004-12-06 2007-09-05 Themis Laboratories Private Limited Sulfonylurea compositions and a process for its preparation
DE102005014141B4 (de) * 2005-03-23 2006-12-21 Hennig Arzneimittel Gmbh & Co. Kg Tablettenförmige Retardzubereitung gegen Schwindel
EP1868587A2 (en) * 2005-04-08 2007-12-26 Abbott Laboratories Pharmaceutical formulations comprising fenofibric acid and/or its salts
JP5046501B2 (ja) * 2005-08-18 2012-10-10 帝人ファーマ株式会社 複数の薬物を分離して保持する錠剤
US9028867B2 (en) * 2005-08-18 2015-05-12 Teijin Pharma Limited Formulation having accurate dose-dividing function
BRPI0615860B8 (pt) * 2005-09-09 2021-05-25 Labopharm Barbados Ltd composição farmacêutica de liberação prolongada monolítica sólida
JOP20180109A1 (ar) * 2005-09-29 2019-01-30 Novartis Ag تركيبة جديدة
JP5361188B2 (ja) * 2006-08-10 2013-12-04 武田薬品工業株式会社 医薬組成物
WO2008062470A2 (en) * 2006-10-19 2008-05-29 Torrent Pharmaceuticals Limited Stabilized controlled release dosage form of gliclazide
JP2008208078A (ja) * 2007-02-27 2008-09-11 Takada Seiyaku Kk 分割錠剤

Also Published As

Publication number Publication date
AR067993A1 (es) 2009-10-28
AU2008207680A1 (en) 2009-10-08
FR2928836A1 (fr) 2009-09-25
AP2729A (en) 2013-08-31
SG155819A1 (en) 2009-10-29
CO6020017A1 (es) 2009-03-31
CN101347414A (zh) 2009-01-21
AP2008004614A0 (en) 2008-10-31
IL193611A0 (en) 2009-08-03
US20140221449A1 (en) 2014-08-07
CR10317A (es) 2008-11-26
ZA200807354B (en) 2008-11-26
EP2103302A1 (fr) 2009-09-23
KR20110112266A (ko) 2011-10-12
CN101347414B (zh) 2011-11-23
SA08290555B1 (ar) 2011-07-20
KR101693189B1 (ko) 2017-01-05
EA200801862A1 (ru) 2009-10-30
BRPI0803631A2 (pt) 2011-03-29
JP2009227651A (ja) 2009-10-08
AU2008207680B8 (en) 2010-05-13
CA2629670C (fr) 2012-04-17
KR20150035829A (ko) 2015-04-07
JO3052B1 (ar) 2017-03-15
MX2008011579A (es) 2009-09-21
US20130295176A1 (en) 2013-11-07
US20090238870A1 (en) 2009-09-24
FR2928836B1 (fr) 2011-08-26
MY150660A (en) 2014-02-14
NZ570715A (en) 2010-10-29
TWI396561B (zh) 2013-05-21
MA31218B1 (fr) 2010-03-01
GT200800163A (es) 2010-05-21
HK1127280A1 (en) 2009-09-25
CA2629670A1 (fr) 2008-10-01
CU20080179A7 (es) 2011-04-26
JP2010209103A (ja) 2010-09-24
EP3025706A1 (fr) 2016-06-01
CL2008002486A1 (es) 2008-12-26
ECSP088727A (es) 2008-10-31
CU23970B1 (es) 2013-12-27
KR20090101048A (ko) 2009-09-24
HN2008001466A (es) 2011-04-25
JP5231906B2 (ja) 2013-07-10
PE20090991A1 (es) 2009-07-18
NI200800256A (es) 2010-02-11
TW200940109A (en) 2009-10-01
WO2009125087A1 (fr) 2009-10-15
AU2008207680B2 (en) 2010-04-22
UA86731C2 (ru) 2009-05-12
CR20140334A (es) 2014-08-20
SV2008003023A (es) 2010-07-29
UY31307A1 (es) 2008-10-31

Similar Documents

Publication Publication Date Title
ME01031B (me) Djeljivi galenski oblik koji omogućava modifikovano oslobađanje aktivnog sastojka
BRPI0906962A2 (pt) Composto, e, composição farmacêutica
BRPI0906556A2 (pt) Composto, e, composição farmacêutica
BRPI1012892A2 (pt) composto, e, composição farmacêutica.
BRPI0814299A2 (pt) Preparação sólida, e, métodos para estabilizar um composto em uma preparação sólida, e para produzir uma preparação sólida
BRPI0916689A2 (pt) composição farmacêutica estabilizada, preparação sólida, e, métodos para estabilizar uma composição farmacêutica, e para estabilizar uma preparação sólida.
BRPI1007018A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
BRPI0917681A2 (pt) Composto, e, composição farmacêutica
BRPI1008906A2 (pt) composto, composição farmacêutica, e, uso de um composto.
DK2131813T3 (da) Topiske, farmaceutiske formuleringer
BRPI0918472A2 (pt) composto 2,4-diaminopirimidina
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0910072A2 (pt) composto, composição farmaceutic, e, método para prover anestesia a um mamífero.
BR112012024432A2 (pt) composição farmacêutica de dissolução rápida
BRPI0814821A2 (pt) Composto, composição farmacêutica, e, processo para preparar um composto
BRPI0807078A2 (pt) Composto, e, formulação farmacêutica
BRPI0815821A2 (pt) Composições e métodos que empregam antagonistas nmda para alcançar um efeito poupador de anestésico.
BRPI0906937A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI1009757A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BRPI0912118A2 (pt) composto, composição farmacêutica, e, intermediário sintético
DK2139453T3 (da) Topisk polyaphronsammensætning med vitamin D
BR112012024428A2 (pt) composição farmacêutica de dissolução rápida
BRPI1014125A2 (pt) composto, composição farmacêutica, e, uso de um composto.
BRPI0911772A2 (pt) composto, composição farmacêutica, e, uso do composto.